These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34605947)

  • 1. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
    Laterre PF; Pickkers P; Marx G; Wittebole X; Meziani F; Dugernier T; Huberlant V; Schuerholz T; François B; Lascarrou JB; Beishuizen A; Oueslati H; Contou D; Hoiting O; Lacherade JC; Chousterman B; Pottecher J; Bauer M; Godet T; Karakas M; Helms J; Bergmann A; Zimmermann J; Richter K; Hartmann O; Pars M; Mebazaa A;
    Intensive Care Med; 2021 Nov; 47(11):1284-1294. PubMed ID: 34605947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
    Geven C; Blet A; Kox M; Hartmann O; Scigalla P; Zimmermann J; Marx G; Laterre PF; Mebazaa A; Pickkers P
    BMJ Open; 2019 Feb; 9(2):e024475. PubMed ID: 30782906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock:
    van Lier D; Picod A; Marx G; Laterre PF; Hartmann O; Knothe C; Azibani F; Struck J; Santos K; Zimmerman J; Bergmann A; Mebazaa A; Pickkers P
    Front Med (Lausanne); 2022; 9():1058235. PubMed ID: 36530868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.
    Karakas M; Akin I; Burdelski C; Clemmensen P; Grahn H; Jarczak D; Keßler M; Kirchhof P; Landmesser U; Lezius S; Lindner D; Mebazaa A; Nierhaus A; Ocak A; Rottbauer W; Sinning C; Skurk C; Söffker G; Westermann D; Zapf A; Zengin E; Zeller T; Kluge S
    Lancet Respir Med; 2022 Mar; 10(3):247-254. PubMed ID: 34895483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.
    Geven C; van Lier D; Blet A; Peelen R; Ten Elzen B; Mebazaa A; Kox M; Pickkers P
    Br J Clin Pharmacol; 2018 Sep; 84(9):2129-2141. PubMed ID: 29856470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.
    Mebazaa A; Geven C; Hollinger A; Wittebole X; Chousterman BG; Blet A; Gayat E; Hartmann O; Scigalla P; Struck J; Bergmann A; Antonelli M; Beishuizen A; Constantin JM; Damoisel C; Deye N; Di Somma S; Dugernier T; François B; Gaudry S; Huberlant V; Lascarrou JB; Marx G; Mercier E; Oueslati H; Pickkers P; Sonneville R; Legrand M; Laterre PF;
    Crit Care; 2018 Dec; 22(1):354. PubMed ID: 30583748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
    François B; Lambden S; Fivez T; Gibot S; Derive M; Grouin JM; Salcedo-Magguilli M; Lemarié J; De Schryver N; Jalkanen V; Hicheur T; Garaud JJ; Cuvier V; Ferrer R; Bestle M; Pettilä V; Mira JP; Bouisse C; Mercier E; Vermassen J; Huberlant V; Vinatier I; Anguel N; Levy M; Laterre PF;
    Lancet Respir Med; 2023 Oct; 11(10):894-904. PubMed ID: 37269870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101).
    Karakas M; Jarczak D; Becker M; Roedl K; Addo MM; Hein F; Bergmann A; Zimmermann J; Simon TP; Marx G; Lütgehetmann M; Nierhaus A; Kluge S
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32796765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats.
    Blet A; Deniau B; Geven C; Sadoune M; Caillard A; Kounde PR; Polidano E; Pickkers P; Samuel JL; Mebazaa A
    Intensive Care Med Exp; 2019 May; 7(1):25. PubMed ID: 31093784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model.
    Thiele C; Simon TP; Szymanski J; Daniel C; Golias C; Hartmann O; Struck J; Martin L; Marx G; Schuerholz T
    Shock; 2020 Dec; 54(6):810-818. PubMed ID: 32554994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis.
    Geven C; Peters E; Schroedter M; Struck J; Bergmann A; McCook O; Radermacher P; Kox M; Pickkers P
    Shock; 2018 Dec; 50(6):648-654. PubMed ID: 29324627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis.
    Deniau B; Takagi K; Asakage A; Mebazaa A
    Expert Opin Investig Drugs; 2021 Feb; 30(2):95-102. PubMed ID: 33256482
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates.
    Geven C; Kox M; Blet A; Mebazaa A; Schroedter M; Struck J; Bergmann A; Pickkers P
    Toxicol Appl Pharmacol; 2019 Apr; 369():1-16. PubMed ID: 30822437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial.
    Legrand M; Oufella HA; De Backer D; Duranteau J; Leone M; Levy B; Rossignol P; Vicaut E; Dépret F;
    Trials; 2020 Jul; 21(1):601. PubMed ID: 32611377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
    François B; Wittebole X; Ferrer R; Mira JP; Dugernier T; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Pickkers P; Vandenhende F; Garaud JJ; Sánchez M; Salcedo-Magguilli M; Laterre PF
    Intensive Care Med; 2020 Jul; 46(7):1425-1437. PubMed ID: 32468087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selepressin, a novel selective vasopressin V
    Russell JA; Vincent JL; Kjølbye AL; Olsson H; Blemings A; Spapen H; Carl P; Laterre PF; Grundemar L
    Crit Care; 2017 Aug; 21(1):213. PubMed ID: 28807037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis.
    Geven C; Bergmann A; Kox M; Pickkers P
    Shock; 2018 Aug; 50(2):132-140. PubMed ID: 29324626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
    Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
    Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial.
    Puskarich MA; Kline JA; Krabill V; Claremont H; Jones AE
    JPEN J Parenter Enteral Nutr; 2014 Aug; 38(6):736-43. PubMed ID: 23851424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenomedullin in heart failure: pathophysiology and therapeutic application.
    Voors AA; Kremer D; Geven C; Ter Maaten JM; Struck J; Bergmann A; Pickkers P; Metra M; Mebazaa A; Düngen HD; Butler J
    Eur J Heart Fail; 2019 Feb; 21(2):163-171. PubMed ID: 30592365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.